Literature DB >> 18394318

Anti-cyclic citrullinated peptide antibodies in patients affected by HCV-related arthritis.

A Riccio1, L Postiglione, P La Dogana, A Spanò, C Marzocchella, G Tarantino.   

Abstract

Hepatitis C Virus (HCV) infection can induce immunological disorders with different clinical expressions such as arthritis, Sjogren Syndrome and various forms of vasculitis. Retrospectively, the prevalence of anti-Cyclic Citrullinated peptide antibodies (anti-CCP) in a group of patients affected by HCV-related arthritis with positivity for Rheumatoid Factor (RF) and the eventual correlations with RF and/or Anti-Nuclear Antibodies (ANA) and articular involvement were studied. Thirty patients with arthritis were selected from a population of 380 subjects affected by HCV infection. Each patient was evaluated by clinical examination (23 denoted poliarticular and 7 mono-oligoarticular involvement), by X-graphic aspects of joint involvement (8 patients presented joint erosions), by ANA, RF and anti-CCP positivity. Ten of the HCV-related arthritis patients (33.3 percent) presented positivity for anti-CCP, without significant correlation between such parameter and ANA, RF and articular involvement. Anti-CCP resulted positive in 4 out of the 8 patients with joint erosions, and only in 6 out of the 22 patients without joint erosions. Such frequencies analyzed by chi square resulted with no significant differences. Our patients presented an interesting prevalence of the positivity for anti-CCP. These data are cause to consider the specificity recently attributed to this parameter in the diagnosis of rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18394318

Source DB:  PubMed          Journal:  J Biol Regul Homeost Agents        ISSN: 0393-974X            Impact factor:   1.711


  6 in total

1.  Antibodies to mutated citrullinated vimentin in patients with chronic hepatitis C virus genotype IV infection-related arthropathy.

Authors:  M Zehairy; E Soliman; A Daghaidy
Journal:  Rheumatol Int       Date:  2011-11-09       Impact factor: 2.631

2.  Hepatitis C virus infection and its rheumatologic implications.

Authors:  Zeynel A Sayiner; Uzma Haque; Mohammad U Malik; Ahmet Gurakar
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-05

Review 3.  Antibodies against cyclic citrullinated peptides in infectious diseases--a systematic review.

Authors:  Isabella Lima; Mittermayer Santiago
Journal:  Clin Rheumatol       Date:  2010-08-05       Impact factor: 2.980

Review 4.  Rheumatic manifestations of hepatitis C virus chronic infection: Indications for a correct diagnosis.

Authors:  Carlo Palazzi; Emilio D'Amico; Salvatore D'Angelo; Michele Gilio; Ignazio Olivieri
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

5.  The positivity of rheumatoid factor and anti-cyclic citrullinated peptide antibody in nonarthritic patients with chronic hepatitis C infection.

Authors:  E Orge; A Cefle; Ayten Yazici; N Gürel-Polat; S Hulagu
Journal:  Rheumatol Int       Date:  2009-06-23       Impact factor: 2.631

6.  Serum Biomarkers for Discrimination between Hepatitis C-Related Arthropathy and Early Rheumatoid Arthritis.

Authors:  Isabela Siloşi; Lidia Boldeanu; Viorel Biciuşcă; Maria Bogdan; Carmen Avramescu; Citto Taisescu; Vlad Padureanu; Mihail Virgil Boldeanu; Anica Dricu; Cristian Adrian Siloşi
Journal:  Int J Mol Sci       Date:  2017-06-19       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.